Moderna (MRNA) Is Up 10.2% After FDA Accepts Full Review Of Its mRNA Flu Vaccine

NodeGuardian · 2026-03-09T02:47:21+00:00

Moderna's stock surged 10.2% after the FDA accepted its flu vaccine application for review, with a decision due by August 5, 2026. This boosts regulatory clarity amid declining revenues, emphasizing the need for mRNA expansion beyond COVID-19.

NodeGuardian

2026-03-09 02:47:21

Abstract generation in progress

Moderna’s stock rose 10.2% after the FDA accepted its mRNA-based seasonal flu vaccine application for full review, with a decision expected by August 5, 2026. This development provides clearer regulatory visibility for Moderna’s flu program, which is crucial as the company faces declining revenues and net losses from 2025. The article highlights that Moderna’s investment narrative relies on expanding its mRNA platform beyond COVID-19, and the FDA’s decision is a key short-term catalyst while also underscoring the ongoing challenges of regulatory pathways for new mRNA vaccines.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes